Option chain shows key data for AstraZeneca's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for AstraZeneca.

AstraZeneca (OTC:AZNCF) Stock, Option Chain

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.

AZNCF

RIVN

TSLA

Investors like to think of themselves as rational and unattached. Still, the movement of stock prices shows that this isn’t always true — and the existence of technical signals like oversold or undersold

5 Oversold Stocks to Buy Right Now

Biotech

News

Health Care

Movers

General

Earlier today, AstraZeneca plc (NASDAQ: AZN) 

AstraZeneca Abandons Blood Cancer, Cardiovascular Programs Amid Portfolio Prioritization

Earnings

Large Cap

Guidance

AstraZeneca Plc&#39;s (NASDAQ: AZN) unit Alexion has 

AstraZeneca Q2 Earnings Beat Consensus Despite Zero COVID-19 Vaccine Sales, Stock Shoots Up

AstraZeneca PLC

Mawer Investment Management Q4 2024 Quarterly Update

Several large drugmakers will ask the Trump administration to pause Medicare drug price negotiations, even as Biden-appointed officials prepare a n...

Drugmakers to push Trump to pause price negotiations, Bloomberg reports

J.P. Morgan analyst James Gordon maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £140.00. The compan...

J.P. Morgan Keeps Their Buy Rating on AstraZeneca (AZN)

In a report released on January 15, David Evans from Kepler Capital maintained a Hold rating on AstraZeneca (AZN – Research Report), with a price t...

Kepler Capital  Remains a Hold on AstraZeneca (AZN)

The latest update is out from AstraZeneca ( ($GB:AZN) ). AstraZeneca announced the US FDA approval of Calquence in combination with bendamustine an...

AstraZeneca's Calquence Gains FDA Approval for First-Line Mantle Cell Lymphoma Treatment

AstraZeneca's (AZN) Calquence in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with p...

AstraZeneca's Calquence combination approved in U.S.

Guggenheim raised the firm's price target on AstraZeneca (AZN) to 13,100 GBp from 12,600 GBp and keeps a Buy rating on the shares. The firm is upda...

AstraZeneca price target raised to 13,100 GBp from 12,600 GBp at Guggenheim

The Department of Health and Human Services, through the Centers for Medicare & Medicaid Services, announced the selection of 15 additional drugs c...

Ozempic, Xtandi among next 15 drugs selected for U.S. price talks

UK-based AstraZeneca PLC ($GB:AZN) announced that its drug Calquence has won the U.S. FDA approval for treating mantle cell lymphoma (MCL). The com...

AstraZeneca's Calquence Wins FDA Approval for Mantle Cell Lymphoma

The company states: "Datroway, or Dato-DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone...

Comments

AstraZeneca

AstraZeneca (AZNCF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga